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ABSTRACT telomerase is a complex ribonucleoprotein that completes the telomeres' ends in eukaryotic cells which shorten due to DnA underreplication.  
the core enzyme consists of a protein catalytic subunit—telomerase reverse transcriptase (tert)—and telomeric rnA (telomerase rnA (tr)); a small re-
gion of this rnA serves as a template for the telomeric repeats synthesis. Apart from rare exceptions, telomerase is not active in the somatic cells and tissues 
of the human body. However, the activation of telomerase activity in cancer cells was shown for certain in 80–90 % of cases. understanding the mechanism of 
telomerase functioning and the mechanisms of its regulation could be used in oncodiagnostics. telomerase itself and its regulators could be important targets for 
anticancer therapy. the activity of telomerase in a cell is affected by proteins with multiple functions, and this influence is not necessarily specific. there are 
also cases when telomerase regulators act together or when several regulators are organised in the cascade. the aim of this review is to generalize and systemize 
data about the regulation of telomerase in ontogenesis. 
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subunits of reverse transcriptase and two rnA molecules 
[6]. In human telomerase, p23/p90-shaperone, which is re-
sponsible for the complex assembling/configuration, binds 
14-3-3, which is responsible for nuclear localization, and 
tP1 with an unknown function. Proteins hGAr1, Dyskerin/
nAP57, hnHP2, and c1/c2, which are responsible for the 
stability, maturation, and localisation of rnA, bind to the 
htr; La and hStau, which are supposedly responsible for 
the binding to telomeres; L22, which acts in processing and 
nuclear localisation; and hnOP10, A1/uP1, and tP1 with an 
unknown function [7]; tcAB1, which is responsible for the 
localisation of htr in cajal bodies and binding with telom-
ers [8]. the enzymatic activity of human telomerase in the 
rabbit reticulocytes lysate is detected by adding htr and 
htert [9, 10]. note that telomerase functioning in vivo is 
not always consistent with the telomerase activity that was 
measured in vitro. For example, adding the Hemagglutinin 
epitope to the c-end of htert stops telomere alongation 
but does not suppress telomerase activity [11].
In 
1961 Hayflick and Moorhead showed that a so-
matic cell culture has a limited life span [1]. In 1973 
Olovnikov suggested that shortening the chro-
mosomal ends (telomeres) determines the potential number 
of cell divisions. [2]. telomeres protect the cellular genome 
from degradation; they participate in the chromosomal pair-
ing during meiosis and in the gene expression regulation in 
the telomeres region [3]. In immortal cells that can divide 
infinitely, this should be the mechanism for compensating 
the chromosomal shortening. In 1975 Blackburn and Greider 
discovered the enzyme telomerase that elongates chromo-
somes [4].
telomerase is a ribonucleoprotein complex that consists 
of components that are absolutely required for its activity: 
the rnA molecule and telomerase reverse transcriptase 
tert [5]; also, optionally several telomerase-associated pro-
teins could be included in the telomerase complex. tr is also 
a template for tert when telomerase elongates telomeres. 
telomerase exists in human cells as dimers and contains two 52 | ActA nAturAe |  № 1 2009
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telomerase activity detected in vitro appears in leuco-
cytes in the G1 phase (Fig. 1) [12]. On the other hand, tel-
omeres are replicated in vivo during the S-phase (Fig. 1) 
[13, 14]. During most of the cell cycle, tcAB1 helps the htr 
accumulation in cajal bodies [8], and in S-phase it is com-
bined with telomeres in a cell. During the S-phase of the cell 
cycle, htert also moves to telomeres [15, 16]. this means 
that there is regulation at the level of the spatial localisation 
of active telomerase (enzyme) and telomere (substrate). A 
correlation between the telomerase activity and the length 
of telomeres is not always possible to obtain. For example, 
there is no dependency between the length of telomeres and 
telomerase activity in leukaemia [17]. 
the two-step hypothesis of cell aging and immortalisation 
М1/М2 theory describes the activity of telomerase depend-
ency on the number of cell divisions very well (Fig. 2). In em-
bryonic cell lines, telomerase is active and the length of tel-
omeres is constant. In stem cells, the activity of polymerase 
is lower and it only partially compensates the telomeres 
shortening. In somatic cells, telomerase in not active. the 
shortening of telomeres leads to the moment of M1, i.e., the 
achievement of the Hayflick limit (point A on Fig 1) and the 
transition of cells to the senescence (aging) condition, which 
could be rescued by the inactivation or deletion of prB/p16 
or p53. cells that pass through М1 continue their cell divi-
sion and achieve the condition of crisis М2 (point B on Fig 2 ), 
which leads to massive cellular death. cells that survive be-
gin their transformation into cancer cells. cancer cells have 
the ability for unlimited cell division and support the length 
of telomeres (usually due to telomerase activity). In the case 
of the transfection of htr-expressing somatic cells by the 
htert gene (point c on Fig. 2) before the moment of М2, 
they, similarly to cancer cells, demonstrate elongation and 
stabilization of telomeres [7].
telomerase activity, with rare exceptions, does not occur 
in human somatic cells and tissues. Its activity was shown 
in reproductive tissues, as well as in intensively renewing 
tissues, such as some types of blood cells, the intestinal epi-
thelium, and the layer of skin cells [18]; however, the level of 
telomerase activity in the somatic cells with active polymer-
ase is lower than in cancer cells [19].
THE FREquENCy OF TELOMERASE ACTIVITy 
DETECTION IN DIFFERENT TyPES OF TuMORS
telomerase is active in most (80–90%) tumor cells (table 
1), and this activity is the main instrument for supporting 
the telomeres length. there are non-malignant types of tu-
mors and other types of non-cancer lesions that demonstrate 
telomerase activity almost 100% of the time, but there are 
others without any activity [19–21]. tumor cell of some cell 
types can use an alternative mechanism of telomeres length 
support that is based on recombination [22]. In case of the 
transaction of cells with an alternative telomere-supporting 
mechanism by the gene htert, both mechanisms are ac-
tive; however, in the case of the hybridization of cell lines 
with different mechanisms, telomerase is present in hybrids, 
and indications of an alternative mechanism of telomere 
lengthening disappear [23]. It should be noted that telomer-
ase itself is not oncogene. cell lines that were tranfected by 
the htert gene do not demonstrate indications of malig-
nant transformation for a long time [24, 25].
telomerase activity could appear as a result of clone se-
lection in the situation of critical shortening of telomeres [26] 
(Fig. 2, position B). Firstly, cells start to divide intensively, 
and the telomeres shorten; however, only cells with telomer-
ase activation survive. In this case telomerase activity could 
be a marker of malignant progression and negative prog-
nosis. For instance, the main increase of telomerase activ-
ity during lymphogranulomatosis appears at the transition 
between the first and second stages [27]. In other possible 
scenarios, telomerase activity appears at the same time as 
Fig. 1. Cell cycle scheme. The appearance of telomerase activity in vitro 
happens in the G1‑phase, but it works at the S‑phase.
Fig. 2. Dependence of telomeres length on the cell cycle number in 
different types of cells: embryonic cell lines, somatic cells, and hTERT‑
transfected cells.  (А) achieving the Hayflick limit by cells, (B) crisis with 
the following cell death and transformation of surviving cells into cancer 
cells, (C) the transfection of cells by the hTERT gene. reVIeWS
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other cancer-leading metabolic abnormalities as 
a result of original cell damage. In this case tel-
omerase activity appears just at the beginning 
of a disease, and it could be a good marker of the 
beginning of oncological processes. For exam-
ple, there is no dependency between telomerase 
activity and the stage of cancer during cervical 
carcinoma; telomerase is active even at the first 
stage, and its activation occurs in pre-tumor ill-
nesses [28]. telomerase could be active originally 
in the cell types of interest, and this activity just 
becomes stronger during the transition to can-
cer; e.g., as happens during hemoblastosis [26]. 
telomerase also could be originally active in the 
case of the transformation of stem cells [29]. In 
this case telomerase activity will be obtained 
at the beginning of tumor growth, because the 
method of its detection does not allow the activ-
ity from the single cell from the surrounding tis-
sue to be seen, but even a small pool of telomer-
ase-positive cells will be detected. 
unfortunately, most publications provide in-
formation only about the presence of telomerase 
activity in certain types of cancer. the mecha-
nisms of telomerase activation are usually inves-
tigated in a cell culture, and it is not often possi-
ble to conclude by which mechanism and how 
often they are met in the cancer under study in 
vivo. 
THE AMPLIFICATIONS OF HTR AND HTERT GENES
the htr gene has one copy and is located in the 
chromosome 3 at the position 3q26.3. this chro-
mosomal region is amplified, for example, in the 
case of cervical cancer, lung cancer, and squa-
mous cell carcinoma of the head and neck. the 
number of copies of the htr gene increases in 
tumor cells more than in normal cells, and, corre-
spondingly, the htr expression increases in the 
case of cervical cancer, lung cancer, and squa-
mous cell carcinoma of the head and neck [42].
the htert gene is located in chromosome 5 
at the position 5q15.33 in the region that is also 
amplified in some types of cancer [42]. Because 
the amplification of telomerase genes occurred 
during the amplification of chromosomes with 
those genes but not in the locus-specific amplifi-
cation, it is possible to conclude that this process 
is nonspecific. In the case of cervical squamous 
cell carcinoma, the expression of htert is not 
related to the amplification of htert [43]. On 
the other hand, this amplification could possibly 
occur as a result of the chromosomal instability 
and aneuploidy that happens during the critical 
shortening of telomeres. 
REGuLATION OF TERT TRANSCRIPTION
htert transcription is very low or not detected at 
all in most human tissues, but it often appears in 
these tissues after neoplastic transformation [44].
Table 1. Frequency of telomerase activity in different types of tumors. 
Type of tumor
Frequency of 
telomerase 
activity , %
Number of 
researched 
samples
[Reference]
MALIgNANT TUMORS:
small-cell lung cancer
100 15 [21]
90 10 [30]
non-small-cell lung cancer
78
83
84
125
68
32
[21]
[31]
[30]
phlegm from lung cancer patients 67,6 34 [30]
Stomach cancer 72 85 [21]
colon cancer  89 138 [21]
Pancreas cancer 95 43 [21]
Liver cancer
86
79
173
24
[21]
[32]
Mammary gland cancer 
88
59
339
44
[21]
[33]
cervical cancer  100 16 [21]
Ovarian cancer 91 23 [21]
Prostate cancer 90 58 [21]
Kidney cancer 83 115 [21]
William cancer
100
95,7
6
164
[21]
[34]
retinoblastoma 50 34 [21]
neuroepithelial tumors 62 107 [35]
Glioblastoma
75
72
28
26
60
47
25
38
[21]
[35]
[36]
[37]
Astrocytoma, II stage 20 15 [35]
Oligodenryogliomas
100
100
19
4
[21]
[35]
Oligodenryoglioma, II stage 14 14 [37]
Anaplastic oligodenrioglioma 43 7 [37]
Anaplastic astrocytoma
10
40
23
20
15
13
[21]
[35]
[37]
neurobalstoma 94 100 [38]
Melanoma  86 7 [21]
Squamous cell carcinoma 83 18 [21]
Basalioma 95 77 [21]
HEMOBLASTOSES:
Lymphima, low level of malignancy 86 14 [21]
Lymphima, high level of malignancy 100 16 [21]
Malignant lymphoma of cnS 83 12 [39]
Myelodisplastic syndrome 67 6 [21]
cgronic myeloleucosis 71 42 [21]
cgronic myeloleucosism, acceleration phase 100 21 [21]
cgronic myeloleucosis, early stage 14 14 [21]
cgronic myeloleucosis, late stage  57 7 [21]
Acute myeloblastic leucosis 73 64 [21]
Acute lymphoblastic leucosis 80 5 [21]
Lymphogranulematosis (lymphoid predominance) 63,6 33 [40]
Lymphogranulematosis (nodular sclerosis ) 89,7 39 [40]
Lymphogranulematosis (mixed-cells variant) 96,1 26 [40]
Lymphogranulematosis (lymphoid exhaustion) 100 7 [40]
NON-MALIgNANT DISEASES:
Adenoma of colon 45 44 [21]
Hepatitis/liver cirrhosis  
(activity is weaker than in case of liver cancer)
29
8/24
25/45,9
148
24/34
80/37
[21]
[32]
[41]
Mammary gland fibroadenoma 75 12 [21]
Leiomyoma  0 14 [21]
Meningomyoma 0 25 [36]
non-malignant lesion of lymphatic vessel  33 15 [21]
non-malignant lesion of amygdalae   100 23 [21]54 | ActA nAturAe |  № 1 2009
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STRuCTuRE OF THE TELOMERASE REVERSE 
TRANSCRIPTASE PROMOTER 
the htert promoter does not contain ТАТА or СААТ, 
which are typical for the binding of PnA-polymerase II, and 
it is Gc-rich. there are different data on the position of the 
region of the transcription's initiation. note that, now and 
further in this paper, we use the numeration of nucleotides 
(point + 1 bp (nucleotide base pairs)) from point A in the tri-
plet AtG, which is the beginning of translation. It was shown 
[45] (using the method of anti-rnAse protection) that there 
are several protected regions in different htert-positive cell 
lines, which indicates the possibility of several sites of tran-
scription initiation (in the region of from –40 to 100 bp). the 
most commonly protected region in the region of transcrip-
tion initiation is at the position –55  G from the beginning of 
translation. It was shown [46] by analyzing caped mrnA from 
the HeLa cell line that the site of transcription start is at posi-
tion –77 bp. recently, most authors have accepted this view. 
Sites that are responsible for the regulation of htert 
transcription are located in the region of 2000 bp before the 
sites of translation and transcription initiation [47, 48]. the 
most important site for activation is the region from 250–300 
bp before AtG to tens of bp after it [46]. Apart from this, the 
Gc-rich region of the promoter forms cpG-islands near the 
AtG, which indicates that methylation could take part in 
the regulation htert expression [7]. 
the activity of the promoter is related to the distribution 
of its regions for the binding of regulatory proteins, which 
do not interfere with the promoter, but also the transmitters 
of the effects of other regulators. Figure 3 shows the scheme 
of the influence in different effectors on the htert promot-
er; this will be considered further in detail. 
THE METHyLATION OF THE HTERT PROMOTER
In tumor cells, the mutilation profile is different from the 
mutilation profile of normal cells. An analysis of the telom-
erase promoter has shown two cpG-islands; one of them is 
–900 bp from the start codon AtG [49].
In the case of cancer cell lines and intestinal cancer tis-
sues, as has already been shown, there is a htert expres-
sion and cpG-islands of the htert promoter are fully or 
partially mutilated [50]. After extended treatment with the 
demethylation agent 5-aza-2’-deoxicitidine (5azadc) of cell 
lines Lan-1, HeLa, and co115, in which telomerase is active 
and the htert promoter is hyperventilated, a 95% decrease 
in the level of htert-promoter methylation, and a decrease 
of the level of the htert mrnA expression were shown. 
telomerase activity strongly decreases after 2–4 passages of 
cells in the presence of 5azadc [51].
the markers of active chromatin and telomerase expres-
sion are detected when the region of htert-promoter lo-
cated from –73 to +227 bp around the transcription site is 
not methylated [52]. In normal cells, the htert-promot-
er hypermethylation suppresses telomerase activity and 
htert-mrnA expression, and, after treatment by 5azadc, 
telomerase starts to be activated [53]. Analysis of htert-
promoter methylation in patients with chronic В-cells lym-
phoid leucosis has shown that they have high telomerase ac-
tivity but a low level of methylation [49]. there is no direct 
correlation between telomerase activity and the htert-
promoter methylation status for cell lines of ostecarcoma, 
ovarian cancer tissue samples, cervical cancer, and normal 
tissues [54, 55].
this data variation indicates that DnA methylation is not 
a critical factor for telomerase expression regulation in can-
Fig. 3. The scheme of the 
effect of hTERT‑ promoter’s 
transregulators. The inhibitors 
of the hTERT promoter are 
green. Activators are orange. 
Double‑action effectors are 
yellow. → points to the activa‑
tion of the following player of 
cascade, ┤is the inhibition of the 
following cascade player, and 
the absence of an arrow means 
co‑action.reVIeWS
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cer. It occurs together with other disturbances of the system 
of htert-promoter regulation. Apart from this, both meth-
ylation and demethylation could affect telomerase transreg-
ulators, but not the promoter itself. 
THE METHyLATION OF HISTONES OF THE HTERT PROMOTER
Histone methylation, which is provided by methyltrans-
ferases and demethylases, plays an important role in the 
regulation of the chromatin structure and transcription. 
Methyltransferase SMYD3, which is involved in oncogen-
esis, specifically activates htert. this methyltransferase 
binds to its specific binding region on the htert promot-
er and the thrice methylated H3-K4 histone. Suppress-
ing SMYD3 in cancer cells stops H3-K4 threemethylation, 
makes the binding between promoter and trans-activators 
Sp1 and c-Myc weaker, and leads to the decreased acetyla-
tion of Н3 histone in the htert-promoter, which leads to 
a decrease in htert-mrnA and a decrease of telomerase 
activity [56].
THE ACETyLATION AND DEACETyLATION 
OF HTERT-PROMOTER’S HISTONES 
Acetyltransferases Gcn5 and tip60 acetylate histones Н3 
and Н4, which leads to the activation of htert-trancription. 
the same acetyltransferases acetylate Myc, which leads to 
a decrease of its degradation [57] and other proteins that 
are involved in gene transcription, which could nondirectly 
regulate the htert promoter. Acetyltransferase p300 and 
the accompanying cBP are transcription coactivators which 
interact with a lot of sequence-specific transcription fac-
tors, and they are coactivators of onco-suppressor р53 [58]. 
p300 is a coactivator of htert transcription, and the c-Myc 
protein brings this protein to the promoter. even p300 and 
cBP can stabilize Myc in an acetylation-independent man-
ner; acethylation by р300, however, decreases the binding 
level of Myc with the promoter. thus, p300 can participate 
in both activation and the inhibition of the htert promoter. 
the Myc/Max complex is acetylated differently, by p300 
and Gcn5, and is not acetylated by tip60 in vitro, which 
means that the mechanisms of the action of these two trans-
ferases are different [59]. 
Histone deacetylation leads to a decrease in the expression 
of htert [60, 61]. the superexpression of histone deacety-
lases (HDAc1) leads to the suppression of the htert-pro-
moter activity. HDAc1 binds to the telomerase promoter, 
inhibits telomerase activity, and interacts with Sp1 [62]. 
Histone deacetylases can interact with the htert promot-
er through the Mad1 protein, which binds to e-blocks [60, 
62, 63]. Inhibiting histone deacetylation by trichostatin A 
(tSA) leads to the activation of the htert expression; this 
effect depends on Sp1, but not on с-Мус. In the case of Sp1 
superexpression, the effect of tSA is stronger; in the case of 
mutations in the Sp1-binding regions (but not with c-Myc), 
this effect does not occur [63]. Inhibiting histone deacetyla-
tion leads to an increase in the expression and activity of te-
lomerase in normal cells—but not cancer cells (lung cancer 
cell lines)—that already have active telomerase [63, 64]. It is 
reasonable to suggest that, in the case of cancer, deacetyla-
tion is already switched off. 
CASCADE MAPK
the signaling cascade of Mitogen-activated protein kinase 
MAPK, which  is an effector of the extracellular growth 
and stress signals, can regulate the transcriptional activity 
of many promoters by the direct phosphorylation of Sp1 or 
through other mechanisms. the MAPK-signaling Pathway 
is important for htert transcription regulation through 
the number of effectors which bind to the regions in its main 
promoter, including the transcription factors c-Myc, AP-1 
and ets [42]. the inhibition of the MAPK-cascade leads to a 
weakening of the phosphorylation of the estrogen receptor β 
(erβ), to a decrease of the binding of erβ to the htert pro-
moters, and to the respective decrease in the level of htert 
expression [65].
ONCOGENE MyC AND ITS ANTIPODE MAD
e-blocks are located in positions –242 and –34 np of  the 
htert gene, with whose oncoprotein с-Мус interacts, 
which is one of the main htert transcription activators 
[48, 66]. this protein is also a transcriptional activator of a 
number of promoters of other genes, and it is an inhibitor of 
the transcription of genes that are involved in the ceasing of 
cell growth [67].
It was shown that c-Myc expression suppression by anti-
c-Myc antisense-oligonucleotides c-Myc, which was done 
on three leukaemia cell lines, also decreases telomerase ac-
tivity [68]. c-Myc induces htert transcription and telom-
erase activity in normal cells of the epithelium mammary 
glands and primary human fibroblasts [69]. A high level of 
c-Myc leads to the activation of the htert promoter, but 
this effect disappears in the absence of e-blocks [66, 67, 70]. 
Blocking c-Myc bindings has a different effect in different 
cell lines. thus, introducing mutations to the e-block (in po-
sition –242 np in the cells of lines С33А and МЕ180) leads to 
a fall in the htert promoter activity by 70%; however, in 
the cells of cell line SiНa, the same mutations have a very 
small effect. Introducing mutations into the e-block at posi-
tion –34 np provokes a decrease of the htert promoter ac-
tivity by 60% in cells МЕ180; however, htert promoter ac-
tivity changes insignificantly in the cells С33А and SiНa [71]. 
c-Myc-induced htert promoter activation occurs quickly 
and independently of cell proliferation and protein synthesis 
[67, 70]. Heterodimers c-Myc/Max interact directly with the 
htert promoter [61, 66]. 
It is possible that n-Myc is another telomerase activator. 
this gene could be amplified in neurobalstoma at the same 
time as the htert promoter activation [44]. Binding n-Myc 
with the htert promoter has already been shown [72].
the Mad protein is an antipode of  с-Myc; it binds to the 
e-blocks as Mad/Max heterodimers and makes the htert 
promoter activity weaker. the suppression of htert pro-
moter by Mad requires the activity of hitones deacylases. 
However, the inhibition of histone acetylases by tSA is not 
dependent on the presence of e-blocks in the htert pro-
moter [60].
TRANSCRIPTION FACTORS SP1AND SP3
Protein Sp1 regulates several specific promoters which initi-
ate transcription by rnA-polymerase II in vertebrates. Sp1 
binds to the sequence GGGGcGGGGc and similar sequenc-56 | ActA nAturAe |  № 1 2009
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es that are called Gc-boxes. It regulates both htert and 
htr promoters.
there is a set of regions for Sp1 binding in the htert 
that are required for promoter activity [46–48, 71, 73]. 
Similar clusters often exist in other promoters without 
the tAtA-box, and they are required for its complete ac-
tivation [74]. there are five known regions for Sp1 bind-
ing; they are located mainly between the promoter and e-
blocks [46]. two regions for Sp1 binding are identical for 
humans and mice [67]. It is very likely, judging by the ac-
tive promoter regions, that sites for the Sp1 between e-
blocks are involved in this regulation; introducing muta-
tions into those sites leads to a decrease of promoter activity 
of different extents, depending on the mutated site and cell 
line [71]. In the case when those five binding regions are 
switched off, a 90% decrease of the htert promoter activ-
ity occurs, which means that Sp1 is absolutely necessary 
for its activity [60, 71]. Interestingly, that introduction of c-
Myc activates the htert promoter in the presence of Sp1-
binding regions; however, in the absence of those regions, 
the htert promoter activation by c-Myc is insignificant 
[71]. two regions for Sp1 binding located in the region from 
–320 to –350np before the translation site and which are 
not yet well investigated and, possibly, two regions from 
–800 to –1000 np are probably involved in this regulation 
[47]. It is unlikely that other Sp1-binding sites that are fur-
ther away from the transcription beginning site [47] are in-
volved in htert transcription regulation.
Another ubiquitously expressed protein from the Sp pro-
tein family is protein Sp3, which often acts as a concurrent 
inhibitor of Sp1 [75]. changing the ratio of those two pro-
teins in favour of Sp£ leads to the inhibition of htert tran-
scription [76]. 
Both Sp1 and Sp3 are necessary for repressing the htert 
promoter by histone deacetylases; they probably bind them 
to the promoter of tert [77]. Apart from the above stated, 
Sp1 is also a transmitter of both activators and inhibitors of 
htert transcription (Fig 3).
NuCLEAR NF-KB 
nF-kB controls the expression and function of several genes 
involved in cancerogenesis [78] and, in particular c-Myc, 
which is a trans-activator of telomerase. When the protex 
tax of the human Lymphotrophic virus type 1 (HtLV-I, 
Human t-lymphotropic virus I) activates nF-kB, the cas-
cade increase of с-Мус and htert promoters occurs [79]. 
chromatin immunoprecipitation showed that there is an in-
crease in the binding of c-Myc and Sp1 to the htert pro-
moter during its activation by nF-kB [80]. 
the expression of nF-kB and htert genes happens at 
the same time and increases at the early stages of stomach 
cancer formation [81]. the synthesis of htert and potential 
sites for the nF-kB binding in the htert promoter (regions 
–758--749 np and –664--654 np) at the same time allow us 
to suggest that nF-kB participates in telomerase activation 
[82]. the activation of the mtert promoter (as a result of 
binding with nF-kB) was shown for mice [82].
nF-kB (p65 subunit) can interact with histone acetylases 
(HDAc1): because of this, it plays a role in the negative reg-
ulation of gene expression [83]. Histone deacetylases inhibit 
the htert promoter and bind to the promoter with the help 
of Sp1. nF-kB, in the case of binding with the promoter, can 
be used for binding HDAc1. 
TRANSCRIPTION FACTORS  AP1 AND AP2
the transcription factor AP1 (activator protein 1) partici-
pates in the processes of cell proliferation, differentiation, 
cancerogenesis and apoptosis; it is expressed both in cancer 
and normal cells. It is a heterodimer of Jun (c-Jun, JunB or 
JunD) and Fos (c-Fos, FosB, Fra-1 or Fra2) [84].
the super-expression of AP-1 leads to the suppression of 
htert transcription in the HeLa cell line. the combination 
of c-Fos and c-Jun or c-Fos and JunD decreases the activity 
of the htert promoter by 80% in experiments with a short 
time expression. the region of the htert promoter between 
nucleotides –2077 and –455 np participates in this process. 
JunD and c-Jun bind with both potential binding sites of 
AP-1 at positions –1732 and –795 np. Introducing mutations 
in the AP-1- binding sites at the htert promoter compen-
sates AP-1-induced inhibition [84]. the correlation between 
the c-Fos expression, which is one of the АР-1 subunits, and 
the htert mrnA expression was shown [85].
the htert promoter also contains the potential region 
for the AP-2- binding [48, 86]. АР-2 binds with the region 
from –121 to 129 of the htert promoter. In rhabdomyosa-
rcoma cells, the mutation in the AP-2 binding region leads 
to a decrease of promoter activity. At the same time, the su-
per-expression of AP-2 does not lead to an increase in the 
htert promoter’s activity [86].
Fig. 4. Methylation (+Me), Acetylation (+Ac) and De‑acetylation (‑Ac) 
of histons of hTERT promoter. The inhibitors of the hTERT promoter are 
green, activators are orange, and the effectors of double action are yel‑
low. → marks the activation of the following player of the cascade, ┤is the 
inhibition of the following cascade player.reVIeWS
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ONCO-SuPPRESSORS P53 AND P73
Protein p53 regulates plenty of genes that play a role in 
the control of the cell cycle and oncogenesis (p21, MDM-2, 
Bax, c-Fos/Jun, prB, 14-3-3σ, Bcl2 and others) [87–89]. p53 
suppresses oncogenesis by switching on the mechanisms 
of cell cycle arrest and apoptosis as a response to different 
cell damages [87]. this protein is not active in more that 
half of human tumors [90]. recovering the functional р53 
in the case of cervical cancer, Burkitt’s lymphoma, cancer 
of mammary glands, and pancreas leads to  the inhibition 
of telomerase activity through the inhibition of the htert 
expression [91–94]. this effect appears several hours after 
the induction of p53, before the beginning of cell cycle ab-
normalities and apoptosis.
Mutations in the domains of p53, which are responsible 
for histones acetylases and co-repressor Sin3A, do not affect 
htert inhibition; even deacytilases participate in the inhi-
bition of htert transcription by protein p53. p 53 mutations 
in the domain of DnA-binding, oligomerisation domain, or 
domain of transcription activation lead to the deactivation 
of p53 in relation to the telomerase. However, p53 does not 
bind with htert promoter in vivo, which means that its ac-
tion on the promoter is non-direct. p53 can use proteins р21, 
e2F and proteins of group prB [95].
Sp1 is necessary for the inhibition of p53 [92, 94]. Muta-
tions in the regions of Sp1 binding inhibit the htert pro-
moter activity by р53 [92]. experiments on the cells of Dro-
sophila Schneider SL2 have shown that the Sp1-ectopic 
expression-dependent htert-promoter activation is elimi-
nated by wild-type p53. p53 interacts with Sp1 and blocks 
its binding to the htert promoter in vitro [94]. It is possible 
that р53 uses protein p21 as a messenger [95]: however, in 
previous similar experiments it was found that р21 is not a 
messenger between p53 and telomerase [94]. 
Protein p73 has an onco-supressing function similar to 
p53. research on cells without p53 has shown that the su-
per-expression of c-end isoforms p73 (α, β, γ, δ) leads to a 
decrease of htert-promoter activity. the supression of 
htert expression happens with the mediation of the en-
dogenous p73 after the activation of e2F1 in cells. Muta-
tions in the regions of Sp1 binding in the mane region of the 
htert-promoter rescue the repression of the htert-pro-
moter by p73, which means that Sp1 acts as a messenger in 
this process. Apart from this, р73 binds Sp1, which proves 
the participation of Sp1 in the p73-dependent suppression of 
the htert expression [96].
PROTEINS pRB, E2F, p21, AND p16 
Proteins e2F can both suppress and activate oncotransfor-
mation on model systems [97]. the super expression of e2F-
3 correlates with the worst prognosis in the case of prostate 
cancer, ovarian cancer, and nonsmall cell lung cancer; a 
high level of e2F-1 exists in case of lung, mammary, and 
pancreas cancer. A low expression of e2F-1 is obtained in 
case of a more aggressive illness during colon cancer and 
urinary bladder cancer. e2F-1, e2F-2 and e2F-3 are also 
regulated by protein prB, but e2F-4 and e2F-5 are main-
ly regulated by proteins p107 and p130. e2F-1, e2F-2, and 
e2F-3 can bind Sp1, but e2F-4 and e2F-5 do not interact 
with it [98].
Protein e2F-1 binds to the telomerase promoter at twp 
specific regions (at the regions –251 and –175 np). Apart 
from this, there is a nonclassical e2F-1-binding region at 
from –67 to 61 np [99]. e2F-1 decreases the expression of 
htert m rnA and telomerase activity in the cell lines of 
squamous cell carcinoma [99, 100]. the ectopic expression 
of e2F-1, e2F-2, and e2F-3 leads to a decrease in the activ-
ity of the promoter of telomerase reverse transcriptase in 
cell lines HeLa, u2OS, and 273 with the mediation of Sp1; 
e2F-4 and e2F-5 do not inhibit telomerase. However, in the 
htert cells that are not transformed, the activation of en-
dogenous telomerase occurs as an effect of e2F-1,2,3,4,5 
[98].
Other results were obtained when researching [101] the 
cells of squamous cell carcinoma. It was shown that the ac-
tivity of the htert promoter and telomerase activity are 
decreased only by the super-expression of prB: however, 
the super-expression of e2F-1 restores the htert promoter 
acivity. In research on glioblastoma, a correlation between 
the expression of e2F1 and htert was found; patients with 
a low level of e2F-1 expression had a much better prognosis 
[102]. the ectopic expression of exogenous e2F-1 increas-
es the activity of the htert promoter in cell lines Saos-2, 
HeLa, and u-251 MG [102]. the variation in the data could 
be related to the heterogeneity of the cell lines (for exam-
ple, cell line HeLa has been cultured for decades in different 
laboratories, and could be very different depending on the 
source). Another reason for this could be the importance of 
not only the presence of e2F proteins for the inhibition acti-
vation of the htert promoter, by also of their posttransla-
tional modifications and of modifications of prB, which also 
participates in this cascade. 
e2F-1 could be one of the p53 messengers. the mutations 
of the noncanonical region for the binding of e2F-1 and su-
per-expression of the mutant e2F-1, which binds to DnA 
but without the domains of transactivation and binding for 
the prB, lead to the complete compensation of the р53 ef-
fect. the same effect occurs after the inhibition of proteins 
prB, p107, and р130 [95]. 
the super expression of р21 and prB completely sup-
presses the htert expression and stops the cell cycle in the 
cell line u-251 MG [102]. the appearance of protein р21, a 
cycline-dependent kinase inhibitor, leads to the accumula-
tion of the hyperphosphorilated active form of prB, p130, 
and p107. those proteins bind to the proteins of the e2F 
family and transform them from activators of transcrip-
tion to repressors [103]. recovering the expression of prB in 
prB- and p53-negative cancer cells leads to the suppression 
of telomerase activity and stops the cell cycle [104]. the su-
perexpression of the cyclin-dependent kinases cdk2 or cdk4, 
or of cycline D1 or e2F-1, leads to the restoration of prB-
supressed telomerase activity. For the functioning prB as 
an inhibitor of the htert promoter, the phosphorilation of 
prB is critically important [101]. the inhibition effect of prB 
can be explained as binding to e2F-1 with further binding 
to the htert promoter [101] and particularly with bring-
ing additional inhibitors, for example, histone deacrtylases. 
Also, protein prB can disturb the binding of e2F-1 with the 
htert promoter. prB and e2F-1 can also regulate an ex-
pression independently. 58 | ActA nAturAe |  № 1 2009
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Onco-suppressor protein р16 acts in the regulation of the 
prB/e2F system. Its expression significantly decreases the 
level of telomerase activity in glioma cell lines. p16 inhibits 
the binding of Sp1 with its binding regions in the promoter 
[105]. It was shown [100] that р16 insignificantly inhibits te-
lomerase in the cell lines of head and neck epidermoid can-
cer; in [101] it was shown that telomerase activity disappears 
completely in the cell line SSc25, which was transfected by 
the p16-containing vector. 
Bcl2
Bcl2 is one of the apoptotic factors [106]. 
the superexpression of Bcl2 in human cancer cells with 
a low endogenous level of expression of this protein caus-
es an increase in the level of telomerase activity. When the 
Bcl2 expression was switched off and activated after that of 
the cell line ctLL-2, telomerase activity also decreased and 
increased correspondingly and reversibly [107]. When re-
searching the number of mammary gland samples, no corre-
lation between Bcl2 expression and telomerase activity was 
found. Also, after the inhibition of the Bcl2 expression in the 
leukemia cell line HL-60, no changes in htert mrnA ex-
pression were obtained [109]. 
Possibly, the regulation of the expression of htert by 
the protein Bcl2 is not used or used very rarely during nat-
ural ontogenesis; the htert activation by Bcl2 that was 
found is not direct. Another explanation could be that this 
process is tissue-specific. 
ONCO-SuPRESSOR wT1 
Onco-supressor Wt1 participates in the inhibition of telom-
erase activity [110]. In the htert promoter at the position 
-352 np, there is a Wt1-binding site, the mutations in which 
can increase the activity of the htert promoter (it can in-
crease it in cell line 293 but not in cell line HeLa). the su-
perexpression of Wt1 suppresses the expression of htert, 
mrnA, and telomerase activity in cells 293 [110]. Because 
gene Wt1 is expressed in certain types of cells during dif-
ferentiation (kidney, reproductive organs, spleen) [111], the 
role of Wt1 in the telomerase inhibition is probably tissue-
specific. 
MyELOID CELL-SPECIFIC PROTEIN MzF-2 
In the htert promoter, there are four possible regions for 
the binding of transcription factor MZF-2 at the positions 
–687, –619, –543 and –514. they are responsible for sup-
pressing the activity of the htert promoter, and MZF-2 
specifically binds with those regions. the superexpression of 
MZF-2 suppresses the activity of the htert promoter [112]. 
MZF-2 is expressed in cancer telomerase-positive cell 
lines, and it seems that this protein does not play a major 
role in telomerase inhibition [112].
REGuLATOR PROTEIN OF THE uSF GROuP
the htert promoter contains Е-blocks with which not only 
dimmers Myc/Max and Mad/Max can bind, but regulator 
factors uSF as well.
In the model system with a reporter vector, the expres-
sion of uSF1 or uSF2 inhibits the activity of the promoter. 
these proteins do not interact with c-Myc or Mad and do 
not influence their expression in the cell: however, they di-
rectly bind with e-blocks in the htert promoter. Analyz-
ing the clinical cancer and normal samples from the mouth 
has shown that the level of expression of uSF1 and uSF2 is 
lower in the cancer samples, but the htert expression and 
telomerase activity is higher in the cancer samples [113].
According to other data, uSF1 and uSF2 as heterodimers 
act with both the binding regions in the htert promoter 
and do not affect the htert transcription in htert-nega-
tive somatic cells. In htert-expressing cells, these proteins 
activate transcription and participate in the appearance and 
support of the cell immortality [114].
TRANSCRIPTION FACTORS ETS
etS is a family of transcription factors; these proteins con-
tain a conservative DnA-binding domain which specifically 
acts with GGА(A/t) sequences. 
MAP-kinases can phosphorilate proteins etS1 and etS2 
after activation by the epidermal Growth Factor (eGF) and 
its analogue Her2/neu. the phosphorilated form of etS is 
active in transcription. culturing cancer cells А-431, Me180, 
and McF-7 с eGF makes the htert promoter stronger. the 
effect of eGF is compensated after the addition of the MAP-
kinase inhibitor or after removing two supposedly closely 
located regions of etS binding factors with the promoter in 
the region с from –22 to –14 np. eGF can lead to the phos-
phorilation of c-Myc, and, as a result of this, c-Myc activates 
transcription: however, mutations in the regions for c-Myc 
binding in the htert promoter do not affect the ability of 
eGF for transcription activation [115]. etS interacts with 
the htert promoter DnA at the –36 np-position with ac-
tivation, but it interacts at the –293-np position with the 
inhibition of htert expression, forming the complex ets-
Id2-DnA (Id is a family of regulator proteins of cell growth 
and differentiation inhibitors) [116]. the superexpression of 
etS1 and etS2 leads to a decrease and the superexpression 
of Id2 leads to an increase of telomerase activity in the К562 
cell line [117].
Onco-protein Her2/neu activates the transcription of 
htert; it uses the transcription factor er81, a member of 
the etS family, as a messenger. An expression of er81 only 
or Her2/neu in the cell line BJ does not stimulate an ex-
pression of htert mrnA. An expression of both of these 
genes induces the transcription of htert, mrnA, and te-
lomerase activity. In the model system, the expression of 
er81 and Her2/neu increases the promoter activity 3 and 
9 times, correspondingly, and their combined expression in-
creases the promoter activity 37 times (in the cell line 293Т). 
By now, five possible regions for binding have been found, 
and for two of those regions (at the positions +211 –  +214 
np and +313 – +316 np) the ability to bind with er81 has 
been shown. Mutations of only those two regions lead to a 
cooperative decrease of the activation of the htert pro-
moter by er81 and Her2/neu [118]. erK MAP-kinases are 
mediators between Her2/neu and er81. It was also shown 
that ras and raf, which are regulators of erK MAP kinas-
es, stimulate the transcription of htert [118]. 
PeA3 and erM, two other proteins of the etS group 
that are from the same subfamily as er81, in collabora-
tion with Her2/neu, activate the htert promoter, but reVIeWS
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to a lower degree than er81. On the other hand, four tran-
scriptional factors of the etS group from other subfamilies 
(elk1, Sap1a, elf1, and er71) practically do not activate the 
htert promoter [118].
SIGNALING THE PATHwAy OF RECEPTOR CK 
A disturbance of the signaling pathway of the cholesterol-
specific ck receptor was obtained in leukemia patients, in 
the leukemia cell lines, and in the central neural System 
cancer.
the ck active receptor decreases the expression of 
htert mrnA by inhibiting proteinkinase c. Proteinkinase 
c activates the transcription of PPArγ (peroxisome prolifer-
ated receptor γ), which inhibits the expression of c-Myc and 
htert and decreases telomerase activity. Also, PPArγ can 
interact with transcription factor Sp1, which is an activator 
of the transcription of htert. Apart from this, PPArγ is an 
antagonist of nF-kB, which is also an activator of the tran-
scription of htert [119].
STEROID HORMONES
In many cases the probability of oncogenesis can be in-
creased as a result of disturbances in the hormone-medi-
ated regulation of gene expression. Several hormones that 
participate in cancerogenesis could affect the expression of 
htert.
ESTROGENS .  
estrogen (17β-estradiol) activates htert transcription in 
hormone-sensitive tissues. After the treatment of mammary 
gland cancer cells or normal cells of ovarian epithelium by 
estrogen, the level of htert, mrnA, and telomerase activ-
ity increases within a couple of hours [120, 121]. An analy-
sis of the htert promoter has shown that there are two 
regions for esrogen-receptor binding  [122]. the region for 
binding the estrogen receptor at the position –2754 np in-
creases the activity of the promoter by five times as an ef-
fect of the hormone. After removing this region, the acti-
vation htert promoter by estrogen decreases by 70%. the 
second region, at the position –949 np, probably works in 
cooperation with the Sp1 site that is located nearby [123]. 
It was shown using the foot printing approach that protec-
tion of the region at –949 np is effected in the presence of 
estrogen. Mutations of this region strongly decrease the ac-
tivation of the htert promoter by estrogen in the reperter 
construction [121]. In another work it was found that the 
estrogen receptor is bound only with the –2754-np region, 
but not with the –949-np region; it was also found that re-
moving the –949-np region  from the htert promoter does 
not affect the activity of the promoter [120]. Both receptors 
α and β bind to the htert promoter. the low telomerase 
activity in the mammary cancer correlates with the absence 
of the estrogen receptor β [33]. the activation of the htert 
promoter in the cell line nIH3t3 depends on the presence of 
the α estrogen receptor, but not on β [121]. 
the scheme of the multi-level activation of telomerase is 
achieved during estrogen regulation. estrogen activates tel-
omerase not only as a direct regulator, but also through the 
induction of с-Мус, which is another activator of the htert 
promoter [120]. 
estrogen also activates htert expression through the 
PI3K/Akt/nF-kB cascade. estrogen also induces the phos-
phorilation of htert, binding proteins 14-3-3 and nF-kB 
with the htert, and the Akt-kinase mediated accumula-
tion of htert in the nuclei [124]. 
ANDROGENS 
normal prostate tissues and epithelial cell lines usually do 
not have telomerase activity in the presence of androgens, 
but the absence of androgens leads to telomerase activation 
in normal rat prostate tissues and does not produce signifi-
cant changes of telomerase activity in the heart, kidney, liv-
er, and lung tissues [125]. However, most types of prostate 
cancer have strongly expressed telomerase activity at the 
normal level of androgens. In the cell lines of the prostate 
cancer, telomerase activity is suppressed in the absence of 
androgens [126]. Antibody staining has shown a significant 
suppression of telomerase in a set of clinical samples of a 
prostate without androgens [127]. 
In the cell lines of the mammary gland and uterus can-
cer, progesterone increases the mrnA of the telomerase 
reverse transcriptase within three hours of treatment. Af-
ter 12 hours, its amount peaks and starts to decrease; after 
48 hours progesterone opposes estrogen and inhibits the 
estrogen-induced expression of htert mrnA. the acti-
vating effect of progesterone happens through a cascade of 
MAP-kinases, and inhibition happens by p21 [128]. combin-
ing estrogen and progesterone (which models a decrease in 
the risk of mammary gland cancer during pregnancy) leads 
to the suppression of telomerase activity and increases the 
expression of its inhibitors р53 and р21 in the cell line of the 
mammary gland epithelium 76n tert [129].
During the growth of normal and androgen-independent 
prostate cell lines in the presence of dihydrotestosterone, no 
changes in telomerase activity were obtained. In the case of 
an androgen-dependent cell line of LncaP prostate cancer, 
the absence of androgen in the media leads to a decrease in 
telomerase activity. Dihydrotestosterone activates telomer-
ase activity in the G1-phase of the cell cycle. However, there 
was no increase of promoter activity obtained in the experi-
ments with reporter construction [130, 131]. the action of 
androgen is non-direct, and it is consistent with the absence 
of elements of the response to androgen in the promoter of   
htert [126]. 
THE VIRAL REGuLATION OF HTERT ExPRESSION
HuMAN PAPILLOMAVIRuS
Human papillomaviruses (HPV) are divided into 3 groups: 
non-oncogenic, low risk, and high risk by the probability of 
neoplastic transformation of contaminated cells. Proteins 
Е6 and  Е7 of HPV from the high-risk group participate in 
oncogenesis by inactivating cancer suppressors p53 (Е6, to-
gether with Е6АР ubiquitin protein ligase), prB and prB-
associated proteins, p130 and p107 (Е7), and some other pro-
teins [132]. 
After the transfection of telomerase-negative cells (pri-
mary keratinocytes) by genes of Е6 and Е7, only e6 (and not 
e7) activates telomerase [133, 134]. After the transfection of 
cells by both genes (Е6 + Е7), the data is contradictory: the 60 | ActA nAturAe |  № 1 2009
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activation of telomerase can be the same as at transfection 
only with genes Е6 [134], somewhat lower [133], or somwhat 
higher [73]. In the cell line of cervical cancer С33А (with ac-
tive telomerase, but without HPV), an expression of Е6 acti-
vates an expression of htert by 3 times and Е7 by 1.5 times 
[73]. In the line of mammary gland epithelium, Е6 activates 
telomerase almost immediately but Е7 accelerates the proc-
ess of telomerase activity appearance in the cell population 
gradually (high telomerase activity occurs after 20–25 pas-
sages with the expression of Е7) [135]. Shortly, Е6 is a direct 
telomerase activator, and the possible activation of telomer-
ase by the protein Е7 is a mediated and weak effect.
e6 activates telomerase transcription through the pro-
moter region from –260 np until the site of translation ini-
tiation (from –15 to –266 np [134], –258 np [73]), in which 
there are 2 regions of с-Myc binding; when any of these two 
regions are removed, the activity falls by 60% [134]. e6 is co-
precipitated with c-Myc by the immunoprecipitation meth-
od [136]. no changes in the c-Myc expression level after the 
transfection of cells by the gene of Е6 appeared. After the 
superexpression of the gene that encodes Max (protein-an-
tagonist of с Мус), the e6-mediated suppression of htert 
occurs [134]. According to the data of other authors, intro-
ducing mutations into both regions of c-Myc binding leads 
only to a minor decrease of the promoter’s activity. Howev-
er, mutations in Sp1-binding sites lead to a decrease of e6-
induced promoter activity by 50%. Mutations in the regions 
of c-Myc and Sp1 binding at the same time lead to the al-
most complete disappearance of the telomerase transcrip-
tion activation by protein Е6 [73].
In keratinocytes and mammary gland epithelium cells, e6 
from the HPV of a high-risk group (HPV 16, HPV 18, HPV 
31, and HPV 54) has a strong telomerase activation effect; 
however, in the case of HPV from the low-risk group (HPV 
11, APV 6), htert transcription activation is not strong [73]. 
Only the protein Е6 of papillomaviruses from the high-risk 
group binds to the minimal promoter of htert (–300 to +1 
n.p.) [136]. the activation of telomerase by the protein Е6 is 
cell-type specific. the transfection of cells by gene Е6 (which, 
in the case of the cell of uterine cervix epithelium, leads to the 
telomerase activation in the case of foreskin fibroblasts [137] 
or cells IMr90 [69]) does not give a similar effect.
Protein Е2 HPV can inhibit the htert promoter. this 
protein can bind with the htert promoter. For the promot-
er inhibition, the interaction with Sp1 (the binding regions 
which are located between e-blocks) is important. Е2 can in-
hibit the growth of HPV-infected cells and leads HeLa cells 
to apoptosis [138]. 
HEPATITIS B VIRuS
Protein Х of the Hepatitis B virus (HBV) is a transactivator 
whose targets are the genes c-Myc, AP1, AP2, and nF-kB 
[19], which are activators of telomerase.
the frequency of telomerase activity appearance increas-
es from the normal tissue to the cancer tissue: in 79% of can-
cer cases, 24% of cirrhosis, and 8 % of chronic hepatitis [32]; 
in 85,2% of cancer cases, 45,9% of cirrhosis, 25% of chronic 
hepatitis, and 15,7% of normal tissues [41]. 
After the transfection of cell lines by the gene of the pro-
tein Х HB, an increase in the htert mrnA was shown (cell 
lines of hepatic carcinoma and cholangiocarcinoma) [139]. 
Western Blot has demonstrated that the amount of telom-
erase reversed transcriptase increases in the hepatoma cell 
line after the superexpression of the protein Х HBV [140].
A slight increase in c-Мус, together with htert, after 
the superexpression of protein X in the hepatoma cell line 
was also found [140]. Because с-Мус is activated by protein 
Х and activates the expression of htert, it is, possibly, one 
of the mediators in the activation of telomerase after con-
tamination by HBV. However, the relationship between the 
htert mrna expression and the level of c-Myc was not 
found by in situ hybridisation in clinical hepatic cancer sam-
les. Mutations were found in the regions of the с-Мус bind-
ing to the htert in clinical samples of hepatocellular carci-
noma [141]. 
the regions of possible binding of the nuclear hepato-
cellular factors HnF-3b and HnF-5 were found in the pro-
moters of tert in both humans and mice. they are con-
servative, but their functional significance has still not been 
defined [67]. 
HERPES VIRuSES (EPSTEIN–BARR VIRuS, KAPOSI’S SARCOMA) 
Both herpes viruses, which are oncogenic for human, can 
participate in the regulation of the transcription of  htert. 
the epstein–Barr virus (eBV) is a causative agent of 
infectious mononucleosis and is related to cancerogenesis, 
for example, Burkitt lymphoma [19, 142]. the latent mem-
brane protein 1 (LMP1) of eBV induces the specific binding 
of htert with the p65 subunit of nF-kB and the transfer of 
both proteins from the cytoplasm to the nuclei [143]. Another 
mechanism of htert expression activation by the protein 
LMP1 occurs through its с-Мус [144]. the latent membrane 
protein 2A LMP 2A suppresses the transcriptional activity 
of the htert gene [145].
Herpes virus type 8 is identified as a causative agent of 
multiple pigmented sarcoma (Kaposi) [19]. the nuclear anti-
gen LAnA of this virus is an activator of htert transcrip-
tion. this protein can bind with Sp1, and the activation of 
the telomerase promoter probably occurs as a result of this 
interaction [146]. 
T-LyMPHOTROPIC VIRuSES 
t-lymphotropic viruses of the 1st and 2nd types (HtLV-I 
and HtLV-II) activate telomerase [80, 147]. 
All adult patients with acute or chronic t-cell leukemia 
demonstrate a high activity of telomerase; however, non-
symptomatic HtLV-I carriers show telomerase activity only 
in 29% of cases. two out of seven patients with active tel-
omerase transformed to the acute form in one month [148]. 
However, the lack of data (there were only 24 patients) does 
not allow one to draw a definite conclusion about a direct 
relationship between the increase of telomerase activity and 
disease progression. telomerase activity is high in both Ht-
LV-I transformed cells  and in lymphocytes from leukemia/
lymphoma patients when compared with nontransformed or 
normal cells [149].
In the regulation of htert transcription, the protein tax 
of the HtLV-I virus participates; even this protein is on-
cogene: it can suppress the expression of the gene htert 
twice in three days [80, 150] after the stimulation of cell reVIeWS
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division by phytohaemagglutinin. In the absence of phyto-
haemagglutinin and in the presence of a tax, there is an in-
crease of telomerase activity by 25% in the same time span. 
the activation of the expression of nF-kB happens during 
this process, which activates the htert promoter [80]. the 
suppression of the htert promoter activity happens as a 
result of the competition between tax and с-Myc for the ca-
nonic region of c-Myc binding in the htert promoter [150]. 
SV 40 AND ADENOVIRuSES . 
neither SV 40 nor adenoviruses (AV) are related to the ethi-
ology of natural types of human cancers, but in the model 
systems they can act in the transformation.
AV are not oncogenic for human, and gene therapy uses 
them for the creation of genetic material delivery vec-
tors. However, the expression of adenoviral protein Е1А is 
enough for the immortalisation of rodent primary cells, and, 
in the presence of a second oncogene Е2А or ras, their trans-
formation is possible. Protein Е1А 243r and, particullary, 
second exon Е1А, activates the promoters of htert and 
htr. this activation could be suppressed by the repressor 
ctBP (c terminal binding protein), which does not influence 
the basic level of htert expression by its own. the activa-
tion of htert by protein Е1А probably occurs through the 
regions of Sp1 binding [151]. these data show that it is very 
important to be extremely careful with AV and with the 
nonocogenicity–safety of their use in human therapy.
Virus SV 40, which has long been a suspected oncogene, 
is not considered dangerous for humans [152]. In human cell 
lines, big and small SV40 antigens can lead to transforma-
tion [153]. there is data that virus SV40t accelerates the ap-
pearance of telomerase activity in human mammary gland 
epithelial cells. But this activity is dependent on the number 
of passages, which means that telomerase activation may 
happen indirectly and as a result of an increase in the fre-
quency of some random event that happens as a result of 
cell metabolism abnormality [135].
THE EFFECT OF HyPOxIA ON THE HTERT ExPRESSION 
the regions of cancer hypoxia are characterized by resist-
ance to therapy, genetic instability, and by increasing malig-
nancy. Hypoxia can lead to the intensification of telomerase 
activity, for example, in the cell lines of cervical cancer [154]. 
In its main part, the htert promoter contains two regions 
of a hypoxia responsible element (Hre) for binding hypox-
ia-inducible factor-1 (hypoxia-inducible factor-1 and HIF-
1) in the regions –242 and –26 np. It was found that these 
regions are necessary for the activation of htert by HIF-1 
[155]. the incubation of cancer cell lines in the lack of oxy-
gen leads to the assembling of a transcriptional complex that 
includes HIF-1, p300/cBP, rnA-polymerase II, and tFIIB 
on the htert promoter in the region of Hre. the superex-
pression of HIF-1 in the ovarian cell line leads to the growth 
of htert promoter activity by almost two times. During the 
growth of a cancer cell line in the condition of hypoxia with-
out the superexpression of HIF-1, the redistribution of splice 
forms of htert mrnA takes place (see in detail in the sec-
tion “regulation of htert splicing”) with a very insignifi-
cant increase in the total htert mrnA [156]. 
POSTTRANSCRIPTIONAL REGuLATION OF HTERT
cancer needs the support of the telomeres' length, and the 
activity of telomerase that supports the telomeres' length 
may not be in correlation with the transcription of htr and/
or htert mrnA [32]. 
REGuLATION OF HTERT SPLICING 
the telomerase reversed transcriptase gene consists of 16 
exons and makes up ~37,000 base pairs of genomic DnA, in 
which introns make up ~33,000 base pairs and ~4,000 are re-
lated to the transcript [48] (Fig. 5). 
NATuRAL SPLICING OF HTERT MRNA
Only full-sized htert mrnA provides telomerase activ-
ity. thirteen alternative splicing variants of  htert mrnA 
are known [48, 157–159]. Isoform with α-deletion (the dele-
tion of 36 nucleotides in the reverse-transcription domain) 
act, after superexpression, as the dominant inhibitors of tel-
omerase activity [160, 161]. this variant of htert mrnA is 
translated, and the appearing protein can be included in the 
telomerase dimer complex (Fig. 6).
Deletions β and α+β do not lead to the formation of the 
active telomerase, but neither do they inhibit it [161]. How-
ever, after the treatment of immortalized cell lines with the 
tGF β1 (transforming growth factor β1), the β-variant of 
htert mrnA that is formed as a result of alternative splic-
ing and telomerase activity drops [162]. the opposite situa-
tion could exist at the regions of cancer hypoxia: the redis-
tribution from the spliced β-variant to the active transcript 
[156] (Fig. 6).
telomerase activity in the cells of osteosarcoma, which 
express only full-sized mrnA, is higher than in the case of 
cells with a set of different splicing forms of htert mrnA 
[54]. telomerase activity increases in the stomach adenocar-
cinoma tissue, the total amount of htert mrna is increased 
compared to the surrounding tissue, and the ratio of the 
amount of α, β and α+β forms is the same, which indicates 
the absence of regulation of the splicing of htert [163].
the variant with the deletion γ is expressed at a low de-
gree and does not affect telomerase activity in the cell lines 
that were derived from hepatic cancer [159]. Deletions α+β, 
β and 4 insertions InS 1-4 [48, 157] cause the early termi-
nation of htert translation [161] similarly to variants with 
deletions β+γ, α+β+γ [159]. Part of the transcripts that were 
Fig. 5. Gene of telomerase reversed transcriptase. Regions that encode 
N‑ and C‑ ends, reverse‑transcription (RТ), and domains typical for 
telomerases (Т) are shown [48]. 62 | ActA nAturAe |  № 1 2009
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found recently [158] have still not been investigated in rela-
tion to telomerase activity. 
Possibly, splicing telomerase regulation is tissue-specific. 
An analysis of embryonic tissue has shown that telomerase 
activity in the heart and liver correlates with the htert 
gene expression: in a kidney, this activity disappears on the 
15th weak of development, and htert transcripts could be 
found at the 21st week  [164].
ARTIFICIAL SPLICING 
Intron of the first group from tetrahymena can induce new 
rnA, which substitutes htert mrnA with a high accu-
racy and specificity as a result of trance splicing [165]. In the 
cell line of prostate cancer 2’-O-methyl-rnA phosphothio-
ate oligonucleotides, which are specific to the splicing region 
between the 5th intron and 6th exon in htert pre-mrnA, 
there is a decrease in the amount of full-size transcripts and, 
at the same time, an increase in the amount of alternatively 
spliced transcripts, which leads to a decrease in telomerase 
activity. the growth rate decreases in this process, and cells 
start apoptosis within two days [166].
CELLuLAR LOCALIzATION 
even telomerase activity needs the localization of telomerase 
in the nuclei; near the telomeres, a high activity of telomer-
ase in vitro occurs in the cytoplasmatic extract, but not in 
the nuclear extract [167]. However, in vivo GFP-containing 
telomerase is located in the nuclei [168].
When the binding of nF-kB (р65 subunit) with the pro-
tein htert occurs, the tumor necrosis factor  α (TNF α) in-
duces the transfer of nF-kB-bound htert from the cyto-
plasm to the nuclei [169]. 
Protein 14-3-3, which is responsible for nuclear localiza-
tion, binds with telomerase. Dominant-negative 14-3-3 di-
rects htert, which is normally localized in the nuclei, into 
the cytoplasm. Mutant htert, which is incapable of bind-
ing with 14-3-3, localizes in the cytoplasm. 14-3-3 disturbs 
protein crM1 binding with the с neS-motif (nuclear export 
signal). Inhibiting the crM1/exportine1-pathway of the nu-
clear transport, as well as damaging the neS-motif, leads 
to a decrease in the localization of htert in the cytoplasm 
[170].
During most of the cell cycle, htert is not localized in 
the nucleoli, cajal bodies, or telomeres. At the S-phase of 
the cell cycle, htert moves to the nucleoli, then to the ca-
jal bodies, and then to the telomeres [15, 16]. 
THE PHOSPHORILATION AND DEPHOSPHORILATION OF HTERT
the phosphorilation of the telomerase reversed transcriptase 
by the proteinkinase Сα (PKcα) is required for the telomer-
ase activity in mammary-gland cancer cells [171]. Another 
proteinkinase from this group, proteinkinase Сz (PKc zeta), 
controls the telomerase activity in the cell of the cancer of 
the nasopharynx without any effect on htert expression. 
Switching off the PKc-activator zeta cdc42/rac1 leads to a 
decrease of telomerase activity [172] (Fig. 6).
Phosphatase PP2A inhibits telomerase activity in mam-
mary-gland cancer cells [173] (Fig. 7).
the kinase Akt increases telomerase activity by phospho-
rilation htert in the melanoma cell line [174]. the domi-
nant-negative mutant Akt-kinase significantly decreases 
the level of telomerase activity in the endothelial cells. Also, 
it suppresses telomerase activity by inhibiting kinase PI3K 
(phosphoinositol 3-kinase), which phosphorilates and acti-
vates Akt-kinase [175] (Fig. 7).
Phosphorilation not only directly affects the activity of 
htert, but it also affects the transcription of this gene. the 
treatment of cells by the PI3K inhibitor or the expression 
of the dominant-negative Akt-kinase in the cells makes the 
estrogen-activated htert activity weaker in the human 
ovarian carcinoma cell lines [124].
two-strand DnA gaps, activated tyrosin-kinase c-Abl, 
bind and phosphorilate htert, which inhibits its activ-
ity. the irradiation of cells by ionizing radiation induces the 
phosphorilation of htert by the c-Abl-dependent mecha-
nism [176].
under oxidative stress conditions, GtP-ase ran provides 
the export of htert. htert-phosphorilation by kinase 
Scr is required for this export. [177]. the superexpression 
of phosphates Shp-2 blocks this mechanism of exporting 
htert  [178].
THE REGuLATION OF TELOMERASE RNA
In adult human tissues, a high level of telomerase rnA was 
found in primary spermatocytes and in the Sertoli cells, a 
middle level of expression was found in lymphatic follicles, 
and a low level of expression was obtained in the epitheli-
um; htr expression is absent in the neuronal system and in 
Fig. 6. Different variants of splicing of the hTERT mRNA.
Fig 7. Regulating the 
activity of the protein 
hTERT by phospho‑
rilation–dephospho‑
rilation. Activators 
are shown in orange, 
inhibitors are shown 
in green. “+p” 
means phosphorila‑
tion, and “‑p” means 
dephosphorilation. 
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mesenchyme-derived tissues [179]. A significant level of ex-
pression was found in the small intestine, thymus, kidneys, 
and prostate. A low level of htr expression is obtained in 
the brain, liver, stomach, pancreas, lungs, and heart [180].
In telomerase-positive samples of tumor tissues, a strong 
expression of  htr was demonstrated, but only half of tel-
omerase-negative soft tissue sarcomas expresses htr to a 
different degree. In telomerase-negative tumors, there is no 
relation between the expression of htr and the proliferat-
ing status, telomeres length, and expression of htert [181]. 
the high expression of htr is not related to the telomerase 
activity, in lung cancer, for instance [30]. 
using in situ hybridization, it was demonstrated that, in 
the case of Barrett’s esophagus and of early stages of es-
ophageal dysplasia, htr is absent or expressed at a middle 
level; however, the effectiveness of htr expression is high 
at late developmental stages of dysplasia or cancer [182]. 
By using rt-Pcr (reverse transcription and Pcr), htr is 
detected in 90–100% of the samples of lung cancer, both in 
cancer and normal tissues [30, 183]. using in situ hybridiza-
tion, htr is detected only in 26% of cancer tissues that are 
defined by histological analysis; for some samples, a differ-
ence between cancer and normal tissues was obtained. the 
same approach detected an expression of htr in 41% of sq-
uamous cell carcinoma, 13% and 17% of adenocarcinoma of 
mammary gland and ovary, 43% of cancer, and 40% of cervix 
uteri precancerous lesions [34]. unfortunately, the further 
fate of patients with precancerous lesions is unknown, so it 
is impossible to discuss the expression of  htr as a marker 
of oncogenic process development. In order to use htr ex-
pression as a cancer marker, it is necessary to do a precise 
quantitative analysis, unlike the difference in expression of 
htert or determination of telomerase activity.
An analysis of nueroblastoma samples has shown high 
or middle level htr expression in 9 out of 12 samples of the 
middle stages of cancer and only in 2 out of 8 samples of the 
early stages. the illness did not progress in patients with a 
low level or without the expression of htr. In case of eight 
samples of skin cancer taken from seven patients with a 
middle or high level of htr expression, the development of 
diseases was not good. 
It should be mentioned that, in late stages of diseases with 
large metastases (four samples), the expression of htr was 
weak. the expression of htr in the ganglyoneuroblastomas 
and gangloneuromas is located only in neural cells, and it is 
absent in lemmocytes. therefore, htr seems to be a good 
prognostic factor in non-metastasis neuroblastomas [184].
For Williams cancer, htr (but not htert) is a predictive 
factor of further development. In 30% of patients with the 
highest expression of htr (quantitation was done by real-
time Pcr), the probability of relapse was twice as high as in 
patients with the lowest level of htr expression [185]. Also, 
the high level of expression of htr correlates with the bad 
prognosis in patients with lyposarcoma [42].
Increasing htr expression does not always correlate with 
the appearance of telomerase activity [30]. htr inhibits the 
proteinkinase of the Atr checkpoint. Suppressing the level 
of htr expression stops the cell cycle at the G1- and G2- 
phases as a result of the activation of p53 and of the pro-
teinkinase of cHK1 checkpoints. this effect is not depend-
ent on telomerase activity. Increasing the htr expression as 
a response to ultraviolet irradiation stops the activation of 
p53 and cHK1 as a result of the inhibition of Atr activity; 
because of this, it makes the cell response to the DnA dam-
age weaker and allows cells to pass the checkpoint G2/M. 
no interaction between htr and AtM was found, and the 
mechanism of this inhibition is still unknown [186].
REGuLATION OF TRANSCRIPTION OF TELOMERASE RNA 
htr promoter contains ccAAt- and ТАТА-blocks near the 
region of the transcription start and several binding sites for 
the receptors of glucocorticoids, progesterone, androgen, 
and transcription factors АР1 and etS [187]. the minimal 
region of the human telomerase rnA promoter is from –272 
to –42 np prior to the start of transcription. the activity of 
the promoter is maximal when the region before –463 np is 
used; if the size of the region used is larger, the level of tran-
scription decreases [187]. 
Investigating the methylation status of the htr promoter 
has shown that three out of eight telomerase-positive cell 
lines and both telomerase-negative cell lines are hyper-
methylated; however, at the same time, no methylation of 
the htr promoter was obtained either in cancer or in nor-
mal tissues. So, it is very likely that the methylation of the 
promoter is not related to the regulation of the htr expres-
sion [181]. 
htr promoter contains four regions for the binding of 
proteins Sp1/Sp3 (Fig. 8). Sp1-binding activates the pro-
moter, but Sp3 inhibits it [188]. Mutation analysis has shown 
that the region before the ССААТ-block is required for the 
activation of the htr promoter, as well as the fact that three 
regions after ССААТ are responsible for promoter inhibi-
tion. the region immediately after ССААТ has an inhibi-
tion effect at the strongest level but the lowest affinity Sp1. 
this can be explained because it is close to the region of the 
binding of transcription factor nF-Y. two regions just after 
the start of transcription are under complicated regulation; 
Fig. 8. Scheme of the effect of transactivators of hTR promoter. Inhibitors 
of the hTR promoter are green, activators are orange, and cofactors are 
colorless. → means activation of the following cascade player, ┤means inhi‑
bition of the following cascade player, and the absence of an arrow means 
co‑action.64 | ActA nAturAe |  № 1 2009
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the introduction of mutations into both regions results in a 
strong activation effect that is not just the sum of the effects 
of single mutations [189]. On the other hand, research [151] 
has shown that the introduction of mutations into four re-
gions of Sp1-binding at the same time does not affect the 
base level of htr promoter activity, although it disturbs its 
transregulation.
the transcription factor nF-Y, which is capable of re-
cruiting several components of the rnA-polymerase II com-
plex to the promoter [190], is the main activator of the tel-
omerase-reversed transcriptase promoter. nF-Y binds to the 
region ccAAt of the htr promoter, and the disturbances 
of this binding lead to the almost complete disappearance of 
promoter activity [189]. 
prB is also an activator of the htr promoter. the ССААТ 
region is required for its action. the activation of the htr 
promoter by the prB protein decreases in case of mutant 
forms of prB, which are not able to bind e2F, and it disap-
pears in the case of the mutant Δ657 form, which is not able 
to bind e2F or activate gene transcription [188].  
Mytogene-activated proteinkinase kinase 1 – (MeKK1)/
c-Jun-nH(2)-kinase (JnK) suppresses the expression of 
htr. the transfection of the permanently active kinase do-
main of MeKK1, the main MAP3K in the JnK-pathway, 
leads to the strong inhibition of the htr promoter in some 
cancer cell lines. the suppression of the htr promoter by 
kinase MeKK1 could be blocked by the SP600125 inhibitor 
of JnK. the effect of htr-promoter inhibition using kinase 
MeKK1 can be intensified by the co-expression of wild types 
of JnK, but not by the co-expression of the mutant form of 
JnK, which cannot be phosphorylated. the cotransfection 
of Sp3 and MeKK1 gives an additive effect of htr inhibi-
tion. According to immunoprecipitation data, treating cells 
with SP600125 leads to a change in the ratio of Sp1/Sp3 on 
the promoter, increasing Sp1. thus, this kinase helps change 
the Sp1/Sp3 balance on the promoter, increasing Sp3 with-
out changes in the level of expression of Sp1 and Sp3 or the 
inhibition of the htr promoter [191]. 
ubiquitin lygase Mdm2 decreases the stability of р53 and 
regulates the prb/e2F complex [192]. Mdm2 reacts with Sp1 
in vitro and in vivo and inhibits the transcativation of Sp1-
activated promoters. Mdm2 interacts with the promoter of 
htr in vivo and inhibits it; however, regions for Sp1 bind-
ing do not act in this process. Mdm2 suppresses activation by 
prb, nF-Y, and Sp1. Mdm2 and prb, as well as nF-Y, can 
interact with the complex of rnA-polymerase II and, as a 
result, they can affect the expression of htr [190].
the telomerase rnA gene contains the Hre region, and 
HIF-1 binds to this region. Superexpression HIF-1 in the 
cancer cells leads to an almost twofold growth in the activ-
ity of the htr promoter in 6 h of incubation in hypoxia con-
ditions, and then to a decrease back to the normal level in 
4 hours. the transcription complex (including HIF-1, p300, 
rnA-polymerase II, and tFIIB), which was assembled on 
the htr promoter in the cancer cell line in hypoxia condi-
tions, was shown [156]. 
Adenoviral protein e1A increases the expression of the 
reporter vector under the control of the htr promoter by 
2.5 times. this activation likely occurs through the regions of 
Sp1-binding, because their mutations lead to the disappear-
ance of the e1A effect. the activation of the htr promoter 
by the e1A protein is also inhibited by the protein ctBP, but 
it does not influence the basic level of the htr expression 
[151]
THE POST-TRANSCRIPTIONAL REGuLATION 
OF TELOMERASE RNA
tr is accumulated in the cajal bodies in the cancer cell lines, 
but not in the cell lines of the normal cells. It is possible to 
provoke the accumulation of htr in the cajal bodies by the 
expression of the htert in the cells [193]. It is htert that 
is the most important factor of the htr localization in both 
the cajal bodies and on the telomeres [194]. the previous 3’-
end of the htr processing is also required for accumulation 
in the cajal bodies [195]. 
the stability of telomerase rnA in cells can increase 
at oncogenesis. upon expression of htert in the htert-
negative cells, the period of htr half-decay increases by 1.6 
times. this may happen due to binding and stabilization by 
the tr catalic subunit [196]. 
CONTROL OF TELOMERASE ACCESS TO THE TELOMERS 
telomers have a projecting 3’-end which can form several 
structures: Т-loop [197] and G-quadruplexes [198, 199] (Fig. 
9). In the t-loop, the projecting 3’-end is a joint with the in-
ternal region of the telomere and is stabilized by proteins 
[197]. G- are formed by the projecting 3’-end because of the 
formation of Hughstein’s pairs [198, 199]. In humans, six 
proteins (trF1, trF2, hrap1, tIn2, tPP1, and POt1) form 
a Shelterin complex that is a permanent component of hu-
man telomeres [200]. 
changing the level of expression of the Shelterin com-
plex strongly affects the telomerase length. For instance, in-
hibiting trF1 leads to the telomeres lengthening in human 
cancer cells, and its superexpression leads to the shortening 
of telomeres without any changing of the telomerase activ-
ity in vitro. Decreasing the amount of protein tIn2 or the 
superexpression of its mutant alleles, which disturbs tIn2 
Fig. 9. Possible organization of telomere ends: (1) examples of G‑
quadruduplexes, (2) protracting 3’‑end (substrate for telomerase), and 
(3) Т‑loop.reVIeWS
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binding to  trF1 and trF2, leads to telomeres elongation. 
the superexpression of trF2 causes telomere shortening; 
this happens not only because of the in vivo inhibition of te-
lomerase, but also because of the increase in the velocity of 
the shortening. Suppressing tPP1 by rnA interference or 
disturbing the tPP1–POt1 binding also leads to telomere 
elongation, with the following loss of the protein POt1 by 
the telomeres [200]. According to the data of other authors, 
tPP1 and POt1 form a complex with telomeric DnA, which 
increases the activity and processivity of human telomerase. 
It was suggested that tPP1-POt1 switches from inhibiting 
telomerase access to the telomere as a component of Shel-
terin to working as a factor of telomerase processivity dur-
ing the telomere elongation [201]. 
POt1 binds sing-strand telomeric DnA with a high spe-
cificity using two OB-motifs (oligonucleotide/oligosaccha-
ride-binding folds). Without the 1st motif, the superexpres-
sion of POt1 leads to the quick elongation of telomeres [200]. 
Decreasing the hPOt1 expression can also lead to telomere 
elongation [202]. Another group of researchers has found 
that expressing the full-length protein leads to telomere 
elongation [203]. the binding of the recombinant POt1 with 
the telomere oligonucleotide inhibits the binding of telomer-
ase. On the other hand, POt1 in vitro can destroy qudriplex 
structures, which are formed because of Hughstein pairing 
of nucleotides in telomeric DnA. this can explain how POt1 
brings positive participation into the telomerase-dependent 
elongation of telomeres, because G-quadruduplexes seem 
like a very bad substrate for telomerase. the destruction of   
G-quadriduplexes could be also done by helicases Wrn or 
BLM from the family recQ, which react with POt1 [200]. 
In humans, mutations in genes that code helicases Wrn 
or BLM lead to the development of the Blum and Werner 
syndromes, which are characterised by genomic instability 
[204].
Longer telomeres contain more Shelterin complexes, 
which could be a detector of the telomere length. Binding 
the protein POt1 with Shelterin can affect the binding of 
POt1 to the single-strand region of telomere DnA. Also, 
Shelterin can inhibit telomerase and facilitate t-loop forma-
tion, in which one of the 3-ends is not accessible [200].
the amount of POt1 mrnA in the case of stomach can-
cer often decreases in the early stages and increases at more 
advanced stages. the level of POt1 expression decreases 
according to the telomere shortening. Apart from this, the 
inhibition of POt1 in the stomach cancer cell lines by the 
anti-sense oligonucleotides, similarly to the inhibition of tel-
omerase activity, also leads to telomeres shortening [205]. 
the binding of telomerase to the telomeres can be regu-
lated by the formation/degradation of G-quadruduplexes. 
Single-stand DnA-binding protein rPA can untwist the te-
lomeres G-quadruduplexes in the model systems [206]. On 
the other hand, rPA is able to inhibit telomerase activity 
in the model systems by binding with the telomere-imitat-
ing oligonucleotie [207]. the inhibition of telomerase in vitro 
occurs both after removing rPA from the mix and with its 
huge excess [208]. 
unfortunately, the methods for analyzing telomerase ac-
tivity use model systems with an artificial substrate without 
estimating access to the telomeres. 
REGuLATION DuRING THE RESPONSE 
TO THE IONISING IRRADIATION 
When investigating the processes that happen in oncogen-
esis, it is impossible to ignore the consequences of the effect 
of radiation from different sources on the cells. On the one 
hand, it can provoke oncogenesis (uV irradiation provokes 
skin cancer, penetrating ionising radiation can cause dif-
ferent types of cancers, etc.); on the other hand, different 
types of radiations are used in cancer therapy (β-particles, 
neutrons, γ and X rays, etc). Because the activity of telomer-
ase is associated with a lot of different types of cancers, the 
following question occurs: what happens with this activity 
upon radiation? Which leads to another interesting question: 
could irradiation provoke telomerase activity?
While investigating the effect of ionizing irradiation on 
the HeLa cell line, it was found that telomerase activity and 
the amount of htert mrnA increase during the first 24 
hours, until the twofold increase in comparison with the 
non-irradiated samples; however, after that they return to 
their original level within 72 hours [209].
After the application of γ and neutron/γ irradiation to 
the hemopoetic cell line, the increase in telomerase activity 
and in the amount of htert mrnA occurs in a dose- and 
intensity-dependent manner. In the case of neutron/γ irra-
diation, a decrease in telomerase activity occurs first, but it 
is followed by an increase. the influence of irradiation with 
different energies is different in scale and kinetics, but it 
is similar in the mechanism of its action on cells. changes 
in telomerase activity are not related to either the changes 
in the cell cycle or the induction of cell death; they are a 
result of the specific regulator responses to ionizing irra-
diation [210].
HeLa cells with shortened telomeres—after transfection 
by Dn-htert (dominant-negative mutant htert)—be-
come more sensitive to the effect of several chemotherapeu-
tic agents and irradiation. cells transfected by the wild type 
of htert with longer telomeres show higher resistance to 
the chemotherapeutic agents and irradiation [211].
uV irradiation provokes telomerase activity in differ-
ent types of cells, including skin cells. Apart from the skin, 
eyes are also permanently under uV irradiation. It was 
shown that the level of telomerase activity and amount 
of htert mrnA and htr increase only after receiving 
a certain amount of uV-irradiation energy by crystalline 
lens [212].
CONCLuSIONS
Knowing about the system of telomerase regulation allows 
us to create methods and agents for suppressing telomer-
ase activity in cancer cells more effectively. unfortunately, 
many mechanisms of telomerase regulation are tissue-spe-
cific. understanding the interrelationship between the tel-
omerase regulation system and other oncogenes can help in 
developing complex cancer diagnostics, which allows one to 
identify diseases and define the tactics for fighting them at 
the least aggressive stage.   
telomerase activity is a marker of actively dividing cells 
and one of the most universal markers of cancer. 66 | ActA nAturAe |  № 1 2009
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